Page last updated: 2024-12-05
n,n'-diacetylbenzidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N,N'-diacetylbenzidine: induces glomerular epithelial cell lesions; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11942 |
| CHEMBL ID | 1567221 |
| CHEBI ID | 82308 |
| SCHEMBL ID | 3818831 |
| MeSH ID | M0050393 |
Synonyms (74)
| Synonym |
|---|
| CBDIVE_014211 |
| HMS2587G07 |
| n,n'-diacetylbenzidine |
| n,4'-biphenylylenebisacetamide |
| 613-35-4 |
| acetamide,n'-[1,1'-biphenyl]-4,4'-diylbis- |
| acetamide,n'-4,4'-biphenylylenebis- |
| nsc-4717 |
| diacetylbenzidine |
| 4,4'-diacetamidobiphenyl |
| benzidine,n'-diacetyl- |
| 4,4'-diacetylaminobiphenyl |
| wln: 1vmr dr dmv1 |
| nsc4717 |
| n,1'-biphenyl)-4,4'-diylbis-acetamide |
| 4,4'-diacetylbenzidine |
| 4',4'''-biacetanilide |
| acetamide, n,n'-[1,1'-biphenyl]-4,4'-diylbis- |
| n,n'-diacetyl benzidine |
| n-[4'-(acetylamino)-1,1'-biphenyl-4-yl]acetamide |
| MLS000682798 |
| smr000312155 |
| nsc 12409 |
| brn 2217711 |
| biphenyl, 4,4'-diacetamido- |
| n,n'-(1,1'-biphenyl)-4,4'-diylbisacetamide |
| n,n'-4,4'-biphenylylenebisacetamide |
| benzidine, n,n'-diacetyl- |
| ai3-08917 |
| ccris 197 |
| nsc 4717 |
| acetamide, n,n'-4,4'-biphenylylenebis- |
| acetamide, n,n'-(1,1'-biphenyl)-4,4'-diylbis- |
| n,n'-(1,1'-biphenyl)-4,4'-diylbis-acetamide |
| hsdb 5078 |
| einecs 210-338-2 |
| n,n'-(1,1'-biphenyl)-4,4'-diylbis-acetamide 4',4'''-biacetanilide |
| nsc12409 |
| nsc-12409 |
| OPREA1_870996 |
| OPREA1_734946 |
| MAYBRIDGE4_003199 |
| NCGC00176103-01 |
| n,n'-biphenyl-4,4'-diyldiacetamide |
| STK122403 |
| HMS1530B09 |
| AKOS000495581 |
| n-[4-(4-acetamidophenyl)phenyl]acetamide |
| C19217 |
| unii-2ee5599gqs |
| 4-13-00-00373 (beilstein handbook reference) |
| 2ee5599gqs , |
| FT-0632558 |
| diacetylbenzidine, n,n- |
| 4,4'-diacetylbenzidine [hsdb] |
| n,n'-diacetylbenzidine [iarc] |
| CHEBI:82308 , |
| CHEMBL1567221 |
| SCHEMBL3818831 |
| n-[4'-(acetylamino)[1,1'-biphenyl]-4-yl]acetamide # |
| CZVHCFKUXGRABC-UHFFFAOYSA-N |
| 4,4'-diacetylamino-1,1'-biphenyl |
| n-(4'-acetylamino-biphenyl-4-yl)-acetamide |
| DTXSID9036854 |
| sr-01000596885 |
| SR-01000596885-1 |
| mfcd00048194 |
| 4,4-bis(methoxycarbonyl)-2,2-bipyridine |
| n,n'-(biphenyl-4,4'-diyl)diacetamide |
| Q26840865 |
| n,n'-([1,1'-biphenyl]-4,4'-diyl)diacetamide |
| CS-0362407 |
| n,n'-[1,1'-biphenyl]-4,4'-diylbis-acetamide |
| n-{4'-acetamido-[1,1'-biphenyl]-4-yl}acetamide |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " A preliminary dose-response test showed that NOHDABZ was the most toxic compound; it caused chemical peritonitis and death in each of 4 animals given 70 mumol/kg body weight/injected." | ( Carcinogenicity of benzidine, N,N'-diacetylbenzidine, and N-hydroxy-N,N'-diacetylbenzidine for female CD rats. Garner, CD; Morton, KC; Shirai, T; Wang, CY, 1981) | 0.55 |
| " The nonspecific cytochrome P450 inhibitor SKF-525A (10 microM) exhibited a partial dose-response inhibition (maximum 41% of complete reaction mixture) of N'HA formation, but did not alter NHA formation." | ( Rat liver cytochrome P450 metabolism of N-acetylbenzidine and N,N'-diacetylbenzidine. Davis, BB; Lakshmi, VM; Zenser, TV, 1997) | 0.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| biphenyls | Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| WRN | Homo sapiens (human) | Potency | 39.8107 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 1.9953 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 14.1254 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 15.8489 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 6.3096 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (20)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.36) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||